1 published article · Updated continuously
11 trials tracked for Lennox-Gastaut Syndrome: 10 in phase 3 or 4 and 6 with published results. The most-cited published study has 997 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several interventions demonstrated significant reductions in seizure frequencies for patients with Lennox-Gastaut Syndrome. GWP42003-P showed a reduction in drop seizure frequency of -41.86%, -37.16%, and -17.17% (p=0.0047) 2, and -43.90% or -21.80% (p=0.0135) in a 20 mg/kg/day dose study 5. In the GWP42003-P studies, a significant number of participants achieved at least a 50% reduction in drop seizure frequency [2, 5]. Rufinamide was associated with substantial reductions in tonic-atonic seizures (ranging from -39.3% to -47.6%) and total seizure frequency (ranging from -46.3% to -52.0%) 8, as well as significant reductions in other types of seizures (up to -95%) 8. Rufinamide also showed a reduction in tonic-atonic seizure frequency of -24.20% and -3.25% (p=0.003) and total seizure frequency of -32.90% and -3.05% (p=<0.001) 9. Clobazam resulted in a median reduction of 92.3% to 92.7% in the weekly rate of drop seizures 10.
ZX008 (Fenfluramine Hydrochloride) showed significant reductions in the frequency of seizures resulting in drops compared to placebo (-7.59%, -26.49%, -17.89%, and -34.52%; p=0.0008) 3. In studies involving ZX008, treatment-emergent adverse events (TEAEs) were reported in 83.0% or 96.9% of participants 3, and 75.5% of participants in another study 7. Additionally, tDCS was associated with specific outcomes for the number of seizures after treatment (ranging from 35.53 to 93.43) and the number of epileptic discharges (ranging from 585.33 to 831.43), both reaching statistical significance (p=<0.05) 1.
In a study evaluating Rufinamide, there was no significant difference in Child Behavior Checklist (CBCL) Total Problem T-scores at the end of a 2-year treatment period (p=0.6928) 6.
AI synthesis of 10 cited trials, updated Jul 3, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
